Literature DB >> 12858037

Apomorphine reduces BOLD signal in fMRI during voluntary movement in Parkinsonian patients.

Sören Peters1, Boris Suchan, Joanna Rusin, Irene Daum, Odo Köster, Horst Przuntek, Thomas Müller, Gebhard Schmid.   

Abstract

Our group investigated modulatory effects of apomorphine on cerebral activation patterns during finger tapping movements in seven Parkinson's disease (PD) patients off medication. Cerebral activation was measured according to an established fMRI protocol. Apomorphine application disclosed a reduction of cerebral activation patterns to the contralateral precentral gyrus affecting both clinically affected and unaffected sides; tapping with the unaffected hand additionally revealed activation in the contralateral postcentral gyrus. These findings contradict those of similar functional imaging studies performed in PD to date, which variously found augmentation of cerebral activation patterns in Parkinsonian patients after dopaminergic stimulation. One conceivable explanation for our singular results would be preferred binding of apomorphine to presynaptic dopaminergic receptors, leading to inhibition of endogenous dopamine release and resultant diminished dopaminergic stimulation, reflected in diminished cerebral activation patterns. These findings warrant future consideration and further investigation of possible central inhibitory effects of dopaminergic therapy in functional imaging studies in PD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12858037     DOI: 10.1097/00001756-200305060-00006

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  9 in total

Review 1.  Pathophysiology of parkinsonism.

Authors:  Adriana Galvan; Thomas Wichmann
Journal:  Clin Neurophysiol       Date:  2008-05-07       Impact factor: 3.708

2.  Hypoactivation of the primary sensorimotor cortex in de novo Parkinson's disease : a motor fMRI study under controlled conditions.

Authors:  Carlo Tessa; Claudio Lucetti; Stefano Diciotti; Lorenzo Paoli; Paolo Cecchi; Marco Giannelli; Filippo Baldacci; Andrea Ginestroni; Claudio Vignali; Mario Mascalchi; Ubaldo Bonuccelli
Journal:  Neuroradiology       Date:  2011-09-17       Impact factor: 2.804

3.  The phenylephrine blood pressure clamp in pharmacologic magnetic resonance imaging: reduction of systemic confounds and improved detectability of drug-induced BOLD signal changes.

Authors:  Raffael Kalisch; Marina Delfino; M Gustavo Murer; Dorothee P Auer
Journal:  Psychopharmacology (Berl)       Date:  2005-09-14       Impact factor: 4.530

4.  Levodopa effects on hand and speech movements in patients with Parkinson's disease: a FMRI study.

Authors:  Audrey Maillet; Alexandre Krainik; Bettina Debû; Irène Troprès; Christelle Lagrange; Stéphane Thobois; Pierre Pollak; Serge Pinto
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

Review 5.  Functional and anatomical magnetic resonance imaging in Parkinson's disease.

Authors:  Alain Dagher; Atsuko Nagano-Saito
Journal:  Mol Imaging Biol       Date:  2007 Jul-Aug       Impact factor: 3.484

Review 6.  Magnetic Resonance Techniques Applied to the Diagnosis and Treatment of Parkinson's Disease.

Authors:  Benito de Celis Alonso; Silvia S Hidalgo-Tobón; Manuel Menéndez-González; José Salas-Pacheco; Oscar Arias-Carrión
Journal:  Front Neurol       Date:  2015-07-03       Impact factor: 4.003

Review 7.  Brain Magnetic Resonance Imaging (MRI) as a Potential Biomarker for Parkinson's Disease (PD).

Authors:  Paul Tuite
Journal:  Brain Sci       Date:  2017-06-16

8.  Is the GABA System Related to the Social Competence Improvement Effect of Aripiprazole? An (18)F-Fluoroflumazenil PET Study.

Authors:  Jung Suk Lee; Jong Doo Lee; Hae-Jeong Park; Maeng-Keun Oh; Ji Won Chun; Se-Joo Kim; Eosu Kim; Jae-Jin Kim
Journal:  Psychiatry Investig       Date:  2013-01-24       Impact factor: 2.505

9.  Accounting for movement increases sensitivity in detecting brain activity in Parkinson's disease.

Authors:  Štefan Holiga; Harald E Möller; Tomáš Sieger; Matthias L Schroeter; Robert Jech; Karsten Mueller
Journal:  PLoS One       Date:  2012-05-01       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.